Beyond Air, Inc.
$141.7K 13 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Celtic Biodevices LLC
Celtic Biodevices LLC reported $141,400.00 across General Payments, Research, and Ownership to 12 physicians and teaching hospitals across 13 transactions.
- $141.4K Below-median payer
- All-tracks total
- 13 Below-median volume
- Transactions
- 12 Below-median reach
- Recipients
- +$4.8K
- General Payments vs PY2023
Celtic Biodevices LLC reported $141,400.00 across all CMS Open Payments tracks (General + Research + Ownership) to 12 physicians and teaching hospitals in Program Year 2024 - ranking #1093 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $137,400.00, averaging $11.8K per recipient.
How Celtic Biodevices LLC's $141.4K all-tracks total breaks down
Celtic Biodevices LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
10/100
Total payments
F
11/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer celtic-biodevices-llc Celtic Biodevices LLC
$141.4K · #1093/1,925 · 0.0% industry · PY2024
- TOT $141.4K
- RANK #1093
- SHARE 0.0%
- TXN 13
- RCP 12
- CAT 1
- GEN $137.4K
- ΔGEN +$4.8K
- TOP1 100.0%
- PY 2024
Volume peers
Nearest volume peer: Beyond Air, Inc. ($141.7K)
Celtic Biodevices LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Celtic Biodevices LLC's CMS-reported General Payments increased by $4.8K (+3.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CELTIC BIODEVICES LLCPY2023: CELTIC BIODEVICES LLCPY2024: CELTIC BIODEVICES LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $132,600.00
- PY2024
- $137,400.00
What the Data Shows for Celtic Biodevices LLC
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Celtic Biodevices LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
12 transactions worth $137.4K make "Consulting Fee" the top general-payment category in the 1-category breakdown below, 100.0% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Celtic Biodevices LLC made 1 types of general payments. "Consulting Fee" is the largest category at $137.4K, 100.0% of General Payments.
How Celtic Biodevices LLC divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $137.4K | 12 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $137,400.00 (100.0%) of $137,400.00 in this company's General Payments records across 1 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Celtic Biodevices LLC
The five named recipients with the highest reported General Payments from this company
- 1
Thomas Sweeney
$137,400.00 across 12 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Celtic Biodevices LLC ranks #1093 of 1,925 by total payments (bottom 43% by spend) but is notably more concentrated than that alone would suggest -- #130 of 1,838 by HHI (top 7% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Belluscura LLC : $20.0K total payments, HHI 10000
- Ferring Sendirian Berhad : $4.3K total payments, HHI 10000
- Sentec, Inc. : $12.3K total payments, HHI 10000
- Advanced Accelerator Applications : $63.9M total payments, HHI 10000
- AxioMed LLC : $1.3K total payments, HHI 10000
- Acerta Pharma LLC : $500.00 total payments, HHI 10000
- Celtic Biodevices LLC (this company) : $137.4K total payments, HHI 10000
- Sensible Medical Innovations Ltd : $36.0K total payments, HHI 10000
- Boehringer Ingelheim USA, Inc. : $26.0K total payments, HHI 10000
- O&M Halyard, Inc. : $239.1K total payments, HHI 10000
- Semler Scientific, Inc. : $112.0K total payments, HHI 10000
- FUJIFILM Holdings America Corporation : $115.00 total payments, HHI 10000
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Celtic Biodevices LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Celtic Biodevices LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Celtic Biodevices LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Archimmune Therapeutics Inc.
$142.0K 1 recipients
Compare payment profiles
Nordic Pharma, Inc.
$142.6K 166 recipients
Compare payment profiles
Accuray Incorporated
$143.0K 278 recipients
Compare payment profiles
Sirius Medical Systems
$139.4K 207 recipients
Compare payment profiles
Besins Healthcare Ireland Limited
$139.1K 16 recipients
Compare payment profiles
Put this to use
Celtic Biodevices LLC ranks #1093 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Celtic Biodevices LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.